Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Transplant Cell Ther. 2021 Dec 5;28(3):157.e1–157.e9. doi: 10.1016/j.jtct.2021.11.023

Figure 2.

Figure 2.

(A) Cumulative incidence of chronic health conditions among 2-year survivors of BMT for IEM by time from BMT. (B) Cumulative incidence of serious, life-threatening, and fatal chronic health conditions among 2-year survivors of BMT for leukodystrophies by time from BMT. The center diamond represents the odds of grade 3–4 chronic health conditions among 2-year survivors of BMT for IEM. The line represents the upper and lower 95% CI for the OR. (C) The cumulative incidence of serious, life-threatening, and fatal chronic health conditions among 2-year survivors of BMT for mucopolysaccharidoses by time from BMT.